Epidermis News and Research

Latest Epidermis News and Research

HDAC inhibitors may be used to fight against skin cancers

In a study published in the journal Developmental Cell, Sarah Millar PhD, professor of Dermatology and Cell & Developmental Biology at the University of Pennsylvania School of Medicine, and colleagues demonstrate that a pair of enzymes called HDACs are critical to the proper formation of mammalian skin.

7 Dec 2010

Syneron launches CO2RE CO2 resurfacing system in US and Canada

Syneron Medical Ltd., the global leader in the medical aesthetic device marketplace, announced today the US Food and Drug Administration (FDA) and Health Canada clearance and commercial launch of its highly flexible CO2RE CO2 resurfacing system. CO2RE is a versatile fractional CO2 system that offers the unique ability to treat both superficial and deep skin layers simultaneously with precision-control over the intensity, pattern and depth of ablation.

30 Nov 2010

Stratatech receives SBIR grant to develop anti-infective living human skin substitute

Stratatech Corp., a privately-held regenerative medicine company, today announced that it has been awarded a $3.5 million Fast-Track SBIR grant to expand the development of its anti-infective living human skin substitute.

17 Nov 2010

New Alma’s Soprano laser technology delivers painless procedure for hair removal

Alma Lasers, Ltd., a leader in laser, light, radiofrequency and ultrasound-based aesthetic devices, unveils the latest in next generation medical laser technology with the debut of its new Soprano(XLi) for laser hair removal and deep dermal heating.

12 Nov 2010

Genentech initiates GDC-0449 Phase II clinical trial in BCC patients

Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).

11 Oct 2010

Defense Department's AFIRM to fund Stratatech's Phase IIb clinical trial of StrataGraft tissue

Stratatech Corp., a regenerative medicine company focused on the commercialization of cell-based, tissue-engineered skin substitute products, today announced that the Defense Department's Armed Forces Institute of Regenerative Medicine will fund the Phase IIb clinical trial of the company's flagship StrataGraft living human skin substitute tissue.

8 Oct 2010

Paper describes new method for studying bacterial infection of orthopedic implants

A research team, co-headed by Dr. Woo Lee and Dr. Hongjun Wang of Stevens Institute of Technology, has published a paper describing a new method that generates three-dimensional tissue models for studying bacterial infection of orthopedic implants. Dr. Joung-Hyun Lee of Stevens, and Dr. Jeffrey Kaplan of the New Jersey Dental School, are co-authors of the research.

7 Oct 2010

Zyclara 3.75% more effective than cryotherapy alone in treatment of Actinic Keratoses: Study

Results from a randomized, double-blinded, placebo-controlled, multicentred study just published in the Journal of Drugs in Dermatology shows that treating Actinic Keratoses (AK) with imiquimod 3.75% (Zyclara®) following cryotherapy was more effective than cryotherapy alone in reducing total AK lesion count and achieving complete clearance of AK.

30 Sep 2010

Enrollment in Derma Sciences DSC127 Phase 2 trial in diabetic foot ulcer healing to conclude September end

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that patient screening in its DSC127 Phase 2 trial in diabetic foot ulcer healing will be completed tomorrow, and that enrollment in the trial will conclude on September 30. This randomized, double-blind, placebo controlled study of up to 75 patients will look at the percentage of diabetic ulcers completely healed over a 12-week period, among other outcomes.

14 Sep 2010

Research on immune system can develop new therapy for inflammation, tumors

In two closely related studies, two teams of Scripps Research Institute scientists have discovered the underlying mechanisms that activate a type of immune cell in the skin and other organs. The findings may lead to the development of new therapies to treat inflammation, wounds, asthma, and malignant tumors.

3 Sep 2010

Scientists develop new combined treatment method for skin cancer prevention

Scientists at The University of Texas Health Science Center San Antonio are on to something that should bring joy to sunbathers everywhere. Studies show that certain plant substances, administered in combinations, have the ability to suppress skin cancer development in susceptible mice.

30 Aug 2010

Kiehl's to introduce Photo-Age Corrector for treating UV damage on skin

With Labor Day fast-approaching and the summer sun almost a thing of the past, women and men across the United States will be in search of fall's must-have skin renewal system to repair and reverse UV damage.

27 Aug 2010

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Results from a randomized study with Zyclara following cryotherapy in the treatment of actinic keratoses (AK) demonstrated Zyclara complemented the effectiveness of cryosurgery in reducing total AK count and achieving complete clearance of AK, according to data presented at the American Academy of Dermatology Summer Academy Meeting 2010 (Summer AAD), August 4 - 8.

7 Aug 2010

Scientists discover mechanism behind flushing reaction caused by nicotinic acid treatment

Cholesterol influences the health of our hearts and blood vessels. Conventional treatment attempts to reduce the level of "bad" cholesterol, LDL cholesterol, in the blood plasma. The opposite approach, which involves increasing the concentration of "good" HDL cholesterol using nicotinic acid, has proven unpopular among patients up to now. The reason for this is that treatment with nicotinic acid has an unpleasant but harmless side-effect: the drug makes patients turn quite red in the face. Scientists at the Max Planck Institute for Heart and Lung Research in Bad Nauheim have now discovered the mechanism behind this effect, which is known as flushing. This will enable the development of flush inhibitors and thereby the more effective prevention of cardiovascular diseases.

27 Jul 2010

StemCell Holding leads CHF 20 million investment in Pantec Biosolutions

Pantec Biosolutions AG, a privately-owned company developing innovative technologies for transdermal drug delivery, today announced the closing of a CHF 20 million investment achieved by two financing rounds. The StemCell Holding AG, an Austrian investment company in the life sciences sector, acted as lead investor.

20 Jul 2010

FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy

DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.

7 Jul 2010

Oxygen can combat wrinkle formation by reducing UVB damage

It's no secret that UVB radiation from the sun causes wrinkles. However, a Japanese study published in the American Journal of Physiology—Regulatory, Integrative and Comparative Physiology (http://ajpregu.physiology.org/) indicates that oxygen may help combat the formation of wrinkles by lessening tissue damage done by UVB rays.

30 Jun 2010

E'shee Clinical Esthetic introduces revolutionary new products for skin care

E'shee Skin Care products are the result of a careful collaboration of skin care professionals, doctors and chemists; these revolutionary new products are the next step in skin care.

19 Jun 2010

New form of artificial human skin

Australian researchers are on the road to the discovery of a new form of artificial human skin that could be a boon to burn victims and other patients needing skin grafts. At present the available skin grafts are only 1 millimeter thick and serve only to replace the top epidermis layer.

14 Jun 2010

New method to analyze molecular activity of cancer drugs for solid tumors using skin biopsies

A research team today reported clinical results of a new method for analyzing the molecular activity of cancer drugs for solid tumors using skin biopsies. The approach, enabled by Cambridge Research & Instrumentation, Inc.'s imaging and analysis systems, was presented in a poster session at the American Association of Cancer Research's Annual Meeting in Washington D.C.

21 Apr 2010

Epidermis News and Research

Latest Epidermis News and Research

HDAC inhibitors may be used to fight against skin cancers

Syneron launches CO2RE CO2 resurfacing system in US and Canada

Stratatech receives SBIR grant to develop anti-infective living human skin substitute

New Alma’s Soprano laser technology delivers painless procedure for hair removal

Genentech initiates GDC-0449 Phase II clinical trial in BCC patients

Defense Department's AFIRM to fund Stratatech's Phase IIb clinical trial of StrataGraft tissue

Paper describes new method for studying bacterial infection of orthopedic implants

Zyclara 3.75% more effective than cryotherapy alone in treatment of Actinic Keratoses: Study

Enrollment in Derma Sciences DSC127 Phase 2 trial in diabetic foot ulcer healing to conclude September end

Research on immune system can develop new therapy for inflammation, tumors

Scientists develop new combined treatment method for skin cancer prevention

Kiehl's to introduce Photo-Age Corrector for treating UV damage on skin

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Scientists discover mechanism behind flushing reaction caused by nicotinic acid treatment

StemCell Holding leads CHF 20 million investment in Pantec Biosolutions

FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy

Oxygen can combat wrinkle formation by reducing UVB damage

E'shee Clinical Esthetic introduces revolutionary new products for skin care

New form of artificial human skin

New method to analyze molecular activity of cancer drugs for solid tumors using skin biopsies

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Epidermis News and Research

Latest Epidermis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in